Health Indicator Report of Cancer Deaths - Prostate Cancer
In New Mexico, prostate cancer is the most commonly diagnosed cancer for African American, Asian, Hispanic and White men, and is the second most commonly diagnosed cancer for American Indian men. Prostate cancer is the leading cause of death from cancer for American Indian men, the second leading cause of death from cancer for African American and White men, and is the third leading cause of cancer death for Asian and Hispanic men in New Mexico.
Average Annual Prostate Cancer Deaths per 100,000 Males by U.S. States, 2017
NotesProstate cancer mortality is defined as malignant neoplasms of the prostate (ICD10: C61).
Data SourceCenters for Disease Control and Prevention, National Center for Health Statistics, CDC WONDER Online Database (http://wonder.cdc.gov).
DefinitionProstate Cancer Deaths per 100,000 population (males) in New Mexico
NumeratorNumber of prostate cancer deaths in New Mexico
DenominatorNew Mexico male population
Healthy People Objective: C-7, Reduce the prostate cancer death rateU.S. Target: 21.2 deaths per 100,000 males
Other ObjectivesOther relevant HP2020 objectives: C-18: Increase the proportion of adults who were counseled about cancer screening consistent with current guidelines
How Are We Doing?The rate of death from prostate cancer among New Mexican men has decreased over the past two decades. New Mexico's prostate cancer mortality rate has been below the Healthy People 2020 goal of 21.8 per 100,000 men since 2010.
How Do We Compare With the U.S.?The prostate cancer mortality rate has declined at a similar rate over the past two decades for both New Mexican men and for men in the United States overall. The New Mexico prostate cancer mortality rate is very similar to the United States rate.
What Is Being Done?According to the Centers for Disease Control and Prevention (CDC), if you are thinking about being screened, you and your doctor should consider: - If you have a family history of prostate cancer - If you are African-American - If you have other medical conditions that may make it difficult for you to be treated for prostate cancer if it is found, or that may make you less likely to benefit from screening - How you value the potential benefits and harms of screening, diagnosis, and treatment The Comprehensive Cancer Program (CCP) encourages men to discuss questions about prostate cancer screening with their doctors.
Evidence-based PracticesThe Comprehensive Cancer Program (CCP) promotes screening recommendations made by the US Preventive Services Task Force (USPSTF). In 2018, the USPSTF concluded that for men ages 55 to 69 years, the decision to undergo periodic prostate-specific antigen (PSA)based screening for prostate cancer should be an individual one. Before deciding whether to be screened, men should have an opportunity to discuss the potential benefits and harms of screening with their clinician and to incorporate their values and preferences in the decision. Screening offers a small potential benefit of reducing the chance of death from prostate cancer in some men. However, many men will experience potential harms of screening, including false-positive results that require additional testing and possible prostate biopsy; overdiagnosis and overtreatment; and treatment complications, such as incontinence and erectile dysfunction. In determining whether this service is appropriate in individual cases, patients and clinicians should consider the balance of benefits and harms on the basis of family history, race/ethnicity, comorbid medical conditions, patient values about the benefits and harms of screening and treatment-specific outcomes, and other health needs. Clinicians should not screen men who do not express a preference for screening.
Available ServicesVisit the New Mexico Department of Health Comprehensive Cancer Program website at: http://archive.cancernm.org/ccp/
Health Program InformationVisit the New Mexico Department of Health Comprehensive Cancer Program website at: http://archive.cancernm.org/ccp/
Page Content Updated On 12/21/2018, Published on 01/07/2019